Holen Sie sich die Stockscreener-App
2.42
3.87%
-0.09
Handel nachbörslich:
2.42
Schlusskurs vom Vortag:
$2.51
Offen:
$2.53
24-Stunden-Volumen:
303.31K
Relative Volume:
0.57
Marktkapitalisierung:
$174.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.34M
KGV:
-1.2079
EPS:
-2.0035
Netto-Cashflow:
$-115.63M
1W Leistung:
+11.19%
1M Leistung:
-6.11%
6M Leistung:
+23.74%
1J Leistung:
+136.56%
1-Tages-Spanne:
$2.38
$2.565
1-Wochen-Bereich:
$2.18
$2.60
52-Wochen-Spanne:
$0.9901
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
617-344-4190
Adresse
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.42 | 181.29M | 0 | -121.34M | -115.63M | -2.0035 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN
Acumen Pharmaceuticals Q1 2026 Earnings: Narrowed Loss Surprises as Alzheimer’s Pipeline AdvancesCapex Guidance - Newser
Acumen Pharmaceuticals (ABOS) Gains Momentum: Support Holds at $2.37, Resistance at $2.61 in FocusValue Area High - Newser
Acumen Pharmaceuticals Q1 earnings call highlights - MSN
Acumen’s Late-2026 Sabirnetug Readout Is A Viable Bet (NASDAQ:ABOS) - Seeking Alpha
Acumen Pharmaceuticals Bets Big on Alzheimer’s Trials - TipRanks
Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS) - The Globe and Mail
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Earnings call transcript: Acumen Pharmaceuticals beats Q1 2026 EPS forecast - Investing.com
Acumen Pharmaceuticals (ABOS) loses 33.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Acumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share Price - TipRanks
Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals 1Q 2026: Net loss $(20.7)M, EPS $(0.33) — 10-Q Summary - TradingView
[10-Q] Acumen Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Acumen expects ALTITUDE-AD top-line results in late 2026 while targeting a mid-2027 IND for 2 EBD candidates - MSN
Acumen Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals, Inc. posts first quarter financial results and reports business momentum - Traders Union
Earnings call transcript: Acumen Pharmaceuticals Q1 2026 results show EPS beat - Investing.com
Earnings call transcript: Acumen Pharmaceuticals Q1 2026 results show EPS beat By Investing.com - Investing.com South Africa
ABOS: Phase II Alzheimer's trial on track, EBD program advances, $128.4M cash supports runway into 2027 - TradingView
Acumen Pharmaceuticals Reports Q1 2026 Financial Results and Anticipates Phase 2 ALTITUDE-AD Data for Alzheimer’s Treatment - Minichart
Acumen Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms - ChartMill
Acumen Updates Q1 Results and Alzheimer’s Pipeline Progress - TipRanks
ACUMEN PHARMACEUTICALS ($ABOS) Releases Q1 2026 Earnings - Quiver Quantitative
Acumen Pharmaceuticals Provides Business Update and Financial Results Highlighting Phase 2 Study Progress for Alzheimer’s Treatment and Future Milestones - Quiver Quantitative
Acumen Pharmaceuticals Q1 net loss narrows - TradingView
Earnings Scheduled For May 12, 2026 - Benzinga
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights - The Manila Times
Acumen Pharmaceuticals (NASDAQ: ABOS) posts Q1 2026 loss but extends cash runway - Stock Titan
Alzheimer’s trial data slated for late 2026 as Acumen holds $128M cash - Stock Titan
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN
How Acumen (ABOS) adapts when conditions change (Bullish Sentiment) 2026-05-08Stock Idea Sharing Hub - newser.com
Acumen Pharmaceuticals Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals to present at Bank of America 2026 Health Care Conference on May 14. - Pluang
Acumen executives take Bank of America health care stage May 14 - Stock Titan
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference - marketscreener.com
Acumen Pharmaceuticals (ABOS.US) will release its earnings report before the market opens on May 12. - Moomoo
How Acumen (ABOS) responds to market challenges (Breakout Watch) 2026-05-06Alpha Picks - newser.com
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026 - Weekly Voice
Acumen sets May 12 earnings update, webcast starts at 8 a.m. ET - Stock Titan
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
ABOS - Finviz
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increases By 46.4% - MarketBeat
Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders - MSN
Research presented by Acumen Pharmaceuticals explores new approach at AAN meeting - Traders Union
Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding - MSN
Acumen (NASDAQ: ABOS) seeks approval for major equity plan expansion - Stock Titan
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acumen Pharmaceuticals Inc-Aktie (ABOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Mar 06 '26 |
Sale |
3.26 |
2,090 |
6,813 |
173,999 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):